

VIDENSKAB OG PRAKSIS | AKADEMISKE AFHANDLINGER

- and early retirement in obese Swedish women. *Int J Obes Relat Metab Disord* 1996;20:895-903.
19. Katzmarzyk PT, Janssen I. The economic costs associated with physical inactivity and obesity in Canada: an update. *Can J Appl Physiol* 2004;29:90-115.
 20. Roux L, Donaldson C. Economics and obesity: costing the problem or evaluating solutions? *Obes Res* 2004;12:173-9.
 21. Raebel MA, Malone DC, Conner DA et al. Health services use and health care costs of obese and nonobese individuals. *Arch Intern Med* 2004;164:2135-40.
 22. Thompson D, Brown JB, Nichols GA et al. Body mass index and future healthcare costs: a retrospective cohort study. *Obes Res* 2001;9:210-8.
 23. Narbro K, Agren G, Jonsson E et al. Pharmaceutical costs in obese individuals: comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: the SOS intervention study. *Arch Intern Med* 2002;162:2061-9.
 24. Agren G, Narbro K, Jonsson E et al. Cost of in-patient care over 7 years among surgically and conventionally treated obese patients. *Obes Res* 2002;10:1276-83.
 25. Sturm R. The effects of obesity, smoking, and drinking on medical problems and costs. *Health Aff (Millwood)* 2002;21:245-53.
 26. Foxcroft DR, Milne R. Orlistat for the treatment of obesity: rapid review and cost-effectiveness model. *Obes Rev* 2000;1:121-6.
 27. O'Meara S, Riemersma R, Shirran L et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. *Health Technol Assess* 2001;5:1-81.
 28. Lamotte M, Annemans L, Lefever A et al. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. *Diabetes Care* 2002;25:303-8.
 29. O'Meara S, Riemersma R, Shirran L et al. The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment. *Health Technol Assess* 2002;6:1-97.
 30. Clarke PM, Gray AM, Briggs A et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). *Diabetologia* 2005;48:868-77.
 31. Clegg AJ, Colquitt J, Sidhu MK et al. The clinical effectiveness and cost-effectiveness of surgery for people with morbid obesity: a systematic review and economic evaluation. *Health Technol Assess* 2002;6:1-153.
 32. Salem L, Jensen CC, Flum DR. Are bariatric surgical outcomes worth their cost? *J Am Coll Surg* 2005;200:270-8.
 33. Salkeld G, Phongsavan P, Oldenburg B et al. The cost-effectiveness of a cardiovascular risk reduction program in general practice. *Health Policy* 1997;41:105-19.
 34. Baum CL, Ford WF. The wage effects of obesity: a longitudinal study. *Health Econ* 2004;13:885-99.
 35. Bhattacharya J, Bundorf MK. The incidence of the health care costs of obesity. New York: National Bureau of Economic Research, 2005: Working Paper 11303 2005.
 36. French SA. Pricing effects on food choices. *J Nutr* 2003;133:841S-843S.
 37. Drewnowski A. Fat and sugar: an economic analysis. *J Nutr* 2003;133:838S-840S.
 38. Cutler DM, Glaeser EL, Shapiro JM. Why have american become more obese. *J Econ Perspect* 2003;17:95-118.
 39. Lakdawalla D, Philipson T. The growth of obesity and technological change: a theoretical and empirical examination. New York: National Bureau of Economic Research, 2002: 8946 2002.
 40. Fogel RW. Economic growth, population theory, and physiology: the bearing of long-term processes on the making of economic policy. *Am Econ Rev* 2001;84:369-95.

> AKADEMISKE AFHANDLINGER

Læge Kristine Bruun Degn:

Effects of two GLP-1 mimetics (liraglutide and exenatide) on aspects of glucose and lipid metabolism and islet cell function in humans during daily life conditions and during hypoglycemia
Ph.d.-afhandling



Forf.s adresse: Søvninget 24, DK-8250 Egå.

E-mail: kbd@dadlnet.dk

Forsvaret finder sted torsdag den 12. januar 2005 kl. 14.00, M-auditoriet, bygning 3, Århus Sygehus, Nørrebrogade 42-44, Århus.

Bedømmere: Jens Juul Holst, Sten Madsbad og Kjeld Hermansen.

Vejledere: Ole Schmitz, Claus Bogh Juhl og Jørgen Rungby.

Læge Jette Bang Joensen:

Randomized double-blinded clinical investigation of roxithromycin versus placebo as secondary and tertiary prevention in patients with peripheral atherosclerosis
Ph.d.-afhandling



Forf.s adresse: Dronninggårds Alle 44 A, DK-2840 Holte.

E-mail: stoervin@tiscali.dk

Forsvaret finder sted 12. januar 2006 kl. 14.00, lokale 21-22 plan 3, Viborg Sygehus, Viborg.

Bedømmere: Henrik Sillesen, Peter Rørdam og Henrik Toft Sørensen.

Vellede: Svend Juul, Jes S. Lindholt, Eskild W. Henneberg og Lars Østergaard.

Læge Henrik Kabr Mathiesen:

MR spectroscopy in relapsing remitting MS
Ph.d.-afhandling

Forf.s adresse: MR-afdelingen, H:S Hvidovre Hospital, Kettegård Allé 30, DK-2650 Hvidovre.

E-mail: henrikm@drcmr.dk

Afhandlingen kan findes på: www.drcmr.dk/MathiesenPhD2004/

Forsvaret finder sted den 12. januar 2006 kl. 14.00, konferencerummet, MR-afdelingen, H:S Hvidovre Hospital, Hvidovre.

Bedømmere: Carsten Thomsen, Nils Koch-Henriksen og Mads Ravnborg.

Vejledere: Olaf B. Paulson, Henrik B. W. Larsson, Per Soelberg Sørensen, chef-fysiker Lars G. Hanson, Jette L. Frederiksen og Egill Rostrup.